Empaveli (pegcetacoplan) — Medica
Immune-complex membranoproliferative glomerulonephritis, primary (IC-MPGN)
Initial criteria
- age ≥ 12 years
- Diagnosis confirmed by biopsy
- Urine protein-to-creatinine ratio ≥ 1.0 g/g
- Estimated glomerular filtration rate ≥ 30 mL/min/1.73 m²
- Patient has been on stable doses of at least ONE of the following for ≥ 12 weeks prior to starting Empaveli: angiotensin converting enzyme inhibitor OR angiotensin receptor blocker OR sodium-glucose transporter-2 inhibitor
- Prescribed by or in consultation with a nephrologist
Approval duration
6 months (initial, continuation criteria not shown in chunk)